Table 1.

Baseline demographic and clinical characteristics (all treated patients)

CharacteristicPatients (N = 92)
Age, median (range), y 67 (37-87) 
Male sex 48 (52) 
Disease stage at diagnosis*  
 I 8 (9) 
 II 12 (13) 
 III 30 (33) 
 IV 41 (45) 
Bone marrow involvement  
 Yes 29 (32) 
 No 55 (60) 
 Not reported 8 (9) 
FLIPI score at diagnosis  
 0-1 8 (9) 
 2 20 (22) 
 3-5 38 (41) 
 Not reported 26 (28) 
Number of prior lines of therapy  
 Median (range) 3 (2-10) 
 2 34 (37) 
 3 19 (21) 
 ≥4 39 (42) 
Disease status at baseline  
 Relapsed 60 (65) 
 Refractory 32 (35) 
Progression from diagnosis to progression after first-line therapy  
 Median (95% CI), y 2.4 (1.7-3.1) 
 <2 y 41 (45) 
 ≥2 y 50 (55) 
Prior radiotherapy 29 (32) 
Prior autologous HCT 15 (16) 
CharacteristicPatients (N = 92)
Age, median (range), y 67 (37-87) 
Male sex 48 (52) 
Disease stage at diagnosis*  
 I 8 (9) 
 II 12 (13) 
 III 30 (33) 
 IV 41 (45) 
Bone marrow involvement  
 Yes 29 (32) 
 No 55 (60) 
 Not reported 8 (9) 
FLIPI score at diagnosis  
 0-1 8 (9) 
 2 20 (22) 
 3-5 38 (41) 
 Not reported 26 (28) 
Number of prior lines of therapy  
 Median (range) 3 (2-10) 
 2 34 (37) 
 3 19 (21) 
 ≥4 39 (42) 
Disease status at baseline  
 Relapsed 60 (65) 
 Refractory 32 (35) 
Progression from diagnosis to progression after first-line therapy  
 Median (95% CI), y 2.4 (1.7-3.1) 
 <2 y 41 (45) 
 ≥2 y 50 (55) 
Prior radiotherapy 29 (32) 
Prior autologous HCT 15 (16) 

Data are reported as n (%), unless noted otherwise.

FLIPI, Follicular Lymphoma International Prognostic Index.

*

Disease stage at diagnosis was not reported for 1 patient.

Close Modal

or Create an Account

Close Modal
Close Modal